Warfarin sodium
(Synonyms: 华法林钠) 目录号 : GC39731
Warfarin (Athrombine K, Coumadin, Coumafene, WARF 42, Zoocoumarin) is one of the most widely used anticoagulant drugs worldwide, used in the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body.
Cas No.:129-06-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Warfarin (Athrombine K, Coumadin, Coumafene, WARF 42, Zoocoumarin) is one of the most widely used anticoagulant drugs worldwide, used in the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body.
| Cas No. | 129-06-6 | SDF | |
| 别名 | 华法林钠 | ||
| Canonical SMILES | O=C1C(C(C2=CC=CC=C2)CC(C)=O)=C([O-])C3=CC=CC=C3O1.[Na+] | ||
| 分子式 | C19H15NaO4 | 分子量 | 330.31 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0275 mL | 15.1373 mL | 30.2746 mL |
| 5 mM | 0.6055 mL | 3.0275 mL | 6.0549 mL |
| 10 mM | 0.3027 mL | 1.5137 mL | 3.0275 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Warfarin sodium Stability in Oral Formulations
Molecules 2021 Nov 1;26(21):6631.PMID:34771040DOI:10.3390/molecules26216631.
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available Warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the amorphous state. This study investigates the apparent instability of the commercially available warfarin liquid oral formulation using Raman and IR spectroscopy, X-ray diffraction, differential scanning calorimetry, UV spectroscopy, and optical microscopy. Warfarin, not its sodium salt, was identified as the undissolved solid existing in the suspension. This was found to be due to the dissociation of sodium salt and the protonation of the warfarin ion in the liquid phase, which triggered the crystallization of the sparingly soluble unsalted form. The coexistence of protonated and unprotonated warfarin ions in the supernatant, as detected by Raman and UV spectroscopy, confirmed this assumption. Study of the dissolution of Warfarin sodium amorphous salt and crystalline sodium clathrate in the placebo and pure water verified the results. The effect of pH and temperature on warfarin precipitation was also explored.
Warfarin sodium. Practitioner beware
J Am Podiatr Med Assoc 1992 Jul;82(7):345-51.PMID:1432651DOI:10.7547/87507315-82-7-345.
The use of Warfarin sodium in the US has increased dramatically over the last 40 years. Warfarin sodium or Coumadin is the most popular oral anticoagulant used in the US. The podiatric physician frequently encounters patients taking this agent and therefore needs to understand its potential impact. This article will familiarize the reader with the history, pharmacology, clinical applications, side effects, and frequent drug interactions encountered with Warfarin sodium.
Molecular Insights into Warfarin sodium 2-Propanol Solvate Solid Form Changes and Disproportionation Using a Low Volume Two-Stage Dissolution Approach
Mol Pharm 2021 Apr 5;18(4):1779-1791.PMID:33689375DOI:10.1021/acs.molpharmaceut.1c00034.
The current research work focuses on understanding the reported discrepancies and our observations in the dissolution profiles of Warfarin sodium tablets and potential patient-based failure modes during oral warfarin therapy. It was hypothesized that freely soluble crystalline Warfarin sodium (WARC) at first transforms into noncrystalline Warfarin sodium (WARNC) under stress conditions. The WARC → WARNC conversion facilitates the rapid formation of the poorly soluble unionized form, which could lead to dissolution failures and potential poor in vivo performance. Depressed warfarin concentrations locally in the gastrointestinal tract (GIT) may in turn lead to inadequate absorption and thereby affect bioavailability. A low volume two-stage dissolution method was developed to mimic in vivo GIT conditions. Warfarin sodium tablets exposed to room temperature and 75% relative humidity for 1 week showed approximately 23% decrease in drug release. The decline in drug release supports the hypothesis that WARNC is converted to the unionized form faster than WARC does under the same conditions. Solid state characterization (powder X-ray diffractometry and differential scanning calorimetry) data demonstrated the disproportionation of Warfarin sodium to unionized warfarin after solubility and dissolution studies. The findings support the hypothesis and a possible failure mode of Warfarin sodium tablets. This work is a second case study from our laboratory on narrow therapeutic index drug products in which the instability of the solid state of the drug substance is potentially responsible for observed clinical failures.
Surgical management of patients on Warfarin sodium
J Oral Maxillofac Surg 1996 Sep;54(9):1115-8.PMID:8811824DOI:10.1016/s0278-2391(96)90172-x.
Purpose: Management of anticoagulated patients has changed significantly over the past 10 years. The change occurred after the introduction of the international normalized ratio (INR) in 1983. This method of reporting prothrombin time for anticoagulated patients has resulted in a decrease in the level at which hematologists and cardiologists keep their patients anticoagulated. Currently, patients are anticoagulated less for the successful prevention of thromboemboli. Recent recommendations are to keep patients anticoagulated to an INR no greater than 3.5. It has been proposed that the extraction of teeth can be performed with INRs of 4 or less. Therefore, the current trend is to maintain patients on their anticoagulation regimens without altering their warfarin dosages. Conclusion: With proper local measures, teeth can be extracted safely and the development of thromboemboli in high-risk patients can still be prevented. However, with procedures having a high risk of bleeding, warfarin dosage may need to be modified.
Warfarin sodium-induced skin necrosis
Ann Emerg Med 1995 Jul;26(1):94-7.PMID:7793729DOI:10.1016/s0196-0644(95)70244-x.
Skin necrosis is a rare complication of treatment with coumarin derivatives. Since it was first identified by Verhagen in 1952, approximately 200 cases of skin necrosis have been reported worldwide, but only 73 have been reported in the English language literature. A telltale clinical scenario of pain and petechiae progressing to sharply demarcated ecchymosis, bullae formation, and gangrenous necrosis manifests most often in the adipose tissues of middle-aged women. Necrosis usually appears within 3 to 6 days of the initiation of Warfarin sodium therapy. We report a case of cutaneous necrosis that began 46 days after Warfarin sodium therapy was begun.